| 项目编号 |
PRJCA042908 |
| 项目标题 |
Anlotinib plus Sintilimab as First-line Treatment for Patients with Advanced Colorectal Cancer (APICAL-CRC): an Open-Label, Single-arm, Phase II trial |
| 涉及领域 |
Medical |
| 数据类型 |
Targeted Locus (Loci)
Transcriptome or Gene expression
|
| 物种名称 |
Homo sapiens
|
| 描述信息 |
This study aimed to evaluate the combination of sintilimab and anlotinib in treatment-naive mCRC patients. This was an investigator-initiated, open-label, single-arm, phase II trial conducted in treatment-naive mCRC patients. Eligible patients received sintilimab 200 mg intravenously on day 1, plus anlotinib 12 mg orally daily from days 1 to 14, with a treatment cycle of every 3 weeks. The primary endpoint was the objective response rate (ORR), assessed by investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. |
| 样品范围 |
Multiisolate |
| 发布日期 |
2025-07-09 |
| 出版信息 |
| PubMed ID |
文章标题 |
杂志名称 |
Doi |
发表年份 |
| 40954146
|
Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): an open-label, single-arm, phase II trial
|
Signal Transduction and Targeted Therapy
|
10.1038/s41392-025-02383-9
|
2025
|
|
|
| 项目资金来源 |
| 机构 |
项目类型 |
授权项目ID |
授权项目名称 |
| Shanghai Changzheng Hospital
|
|
2019SL036
|
|
|
|
| 提交者 |
Dongyu
Liu (dongyu.liu@3dmedcare.com)
|
| 提交单位 |
3D Medicines Inc. |
| 提交日期 |
2025-07-09 |
